RxDoctor Payments Data

Amy Dugger

Nurse Practitioner · Andalusia, ALNPI 1508174236

Payments from drug & device makers

$415in general payments, 2019–2025

Across 12 payments — averaging $34.58 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$152
  • Kerecis Limited$120
  • GSK$35
  • Fresenius USA Marketing, Inc.$33
  • Calliditas Therapeutics US Inc.$22
  • Akebia Therapeutics Inc$19
  • plus $34 from 2 others

What the payments were for

  • Food & beverage$415100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$415 in reported general payments places this provider in the 60th percentile of 1,505 nurse practitioner providers in Alabama.

See all nurse practitioner providers in Alabama

Medicare billing

Part B allowed, 2024
$14,505
Medicare patients
62
Services billed
159

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
VelphoroSucroferric Oxyhydroxide53$105,833
AuryxiaFerric Citrate24$36,965
FarxigaDapagliflozin Propanediol14$13,631
JardianceEmpagliflozin16$12,115
Sevelamer Carbonate35$10,144
Famotidine64$1,415
Lidocaine-PrilocaineLidocaine/Prilocaine78$1,108
Losartan Potassium76$757
Hydralazine Hcl28$456
Potassium Chloride21$378
Furosemide56$356
Carvedilol35$343
Doxycycline Hyclate20$232
Doxazosin Mesylate12$216
Amlodipine Besylate35$185

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Fresenius USA Marketing, Inc.Velphoro$33$105,83353 claims
Akebia Therapeutics IncAuryxia$19$36,96524 claims
AstraZenecaFarxiga$152$13,63114 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 1,505 nurse practitioner providers in Alabama.

Other nurse practitioner in Andalusia

See the full list for Alabama

Where these figures come from

Is this you, or does something look wrong? →